Targetable FGFR3 Fusions and Novel FGFR3 Mutations in Glioma

Jens Schittenhelm; Lukas Ziegler; Michel Mittelbronn; David Capper; Isabel Burghardt; Antti Poso; Saskia Biskup; Marko Skardelly; Ghazaleh Tabatabal

doi:10.1159/000506491

Targetable FGFR3 Fusions and Novel FGFR3 Mutations in Glioma

Jens Schittenhelm
, Lukas Ziegler
, Michel Mittelbronn
, David Capper
, Isabel Burghardt
, Antti Poso
, Saskia Biskup
, Marko Skardelly
, Ghazaleh Tabatabal

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	386
Pages (from-to)	33-33
Journal	Oncology Research and Treatment
Volume	43
Issue number	Suppl.1
DOIs	https://doi.org/10.1159/000506491
Publication status	Published - Feb 2020
Event	Deutscher Krebskongress informativ. innovativ. integrativ. Optimale Versorgung für alle - Berlin, Germany Duration: 19 Feb 2020 → 22 Feb 2020

Access to Document

10.1159/000506491Licence: Unspecified

Cite this

@article{a931d48b52814e2ca5aa900da6c9b8dd,

title = "Targetable FGFR3 Fusions and Novel FGFR3 Mutations in Glioma",

author = "Jens Schittenhelm and Lukas Ziegler and Michel Mittelbronn and David Capper and Isabel Burghardt and Antti Poso and Saskia Biskup and Marko Skardelly and Ghazaleh Tabatabal",

year = "2020",

month = feb,

doi = "10.1159/000506491",

language = "English",

volume = "43",

pages = "33--33",

journal = "Oncology Research and Treatment",

issn = "2296-5270",

publisher = "S. Karger AG",

number = "Suppl.1",

note = "Deutscher Krebskongress informativ. innovativ. integrativ. Optimale Versorgung f{\"u}r alle ; Conference date: 19-02-2020 Through 22-02-2020",

}

TY - JOUR

T1 - Targetable FGFR3 Fusions and Novel FGFR3 Mutations in Glioma

AU - Schittenhelm, Jens

AU - Ziegler, Lukas

AU - Mittelbronn, Michel

AU - Capper, David

AU - Burghardt, Isabel

AU - Poso, Antti

AU - Biskup, Saskia

AU - Skardelly, Marko

AU - Tabatabal, Ghazaleh

PY - 2020/2

Y1 - 2020/2

U2 - 10.1159/000506491

DO - 10.1159/000506491

M3 - Meeting Abstract

SN - 2296-5270

VL - 43

SP - 33

EP - 33

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

IS - Suppl.1

M1 - 386

T2 - Deutscher Krebskongress informativ. innovativ. integrativ. Optimale Versorgung für alle

Y2 - 19 February 2020 through 22 February 2020

ER -